Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Calm After Storm | Range Contraction | 1.34% | |
| Upper Bollinger Band Touch | Strength | 1.34% | |
| Crossed Above 20 DMA | Bullish | 4.05% | |
| Crossed Above 50 DMA | Bullish | 4.05% | |
| New Uptrend | Bullish | 4.05% | |
| 180 Bullish Setup | Bullish Swing Setup | 4.05% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
| Gap Up Partially Closed | about 21 hours ago |
| Gapped Up (Partial) | about 21 hours ago |
| Up 3% | about 21 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.5 |
| 52 Week Low | 12.66 |
| Average Volume | 588,244 |
| 200-Day Moving Average | 23.62 |
| 50-Day Moving Average | 34.36 |
| 20-Day Moving Average | 34.71 |
| 10-Day Moving Average | 36.98 |
| Average True Range | 2.40 |
| RSI (14) | 60.78 |
| ADX | 32.49 |
| +DI | 32.19 |
| -DI | 7.43 |
| Chandelier Exit (Long, 3 ATRs) | 35.31 |
| Chandelier Exit (Short, 3 ATRs) | 37.41 |
| Upper Bollinger Bands | 39.75 |
| Lower Bollinger Band | 29.66 |
| Percent B (%b) | 0.88 |
| BandWidth | 29.07 |
| MACD Line | 1.08 |
| MACD Signal Line | 0.64 |
| MACD Histogram | 0.4408 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 40.60 | ||||
| Resistance 3 (R3) | 40.75 | 40.19 | 40.25 | ||
| Resistance 2 (R2) | 40.19 | 39.66 | 40.12 | 40.13 | |
| Resistance 1 (R1) | 39.35 | 39.33 | 39.07 | 39.20 | 40.02 |
| Pivot Point | 38.79 | 38.79 | 38.66 | 38.72 | 38.79 |
| Support 1 (S1) | 37.95 | 38.26 | 37.67 | 37.80 | 36.98 |
| Support 2 (S2) | 37.39 | 37.93 | 37.32 | 36.87 | |
| Support 3 (S3) | 36.55 | 37.39 | 36.75 | ||
| Support 4 (S4) | 36.40 |
